Kamada Reports Strong Third Quarter Financial Results Demonstrating Successful Strategic Transition and Reiterates 2022 Financial Guidance

Rehovot, ISRAEL


  • Third Quarter 2022 Revenues of $32.2 Million, a 40% Increase Compared to Prior Year Period; Reaping the Benefits of the Acquired IgG Portfolio
  • Strong Results Represent Completion of the Company’s Strategic Transformation into a Diversified Commercial Entity with Multiple Growth Drivers
  • Adjusted EBITDA for the Third Quarter was $6.0 Million, or 19% Margin and for First Nine Months was $10.6 Million or 13% Margin, Within Annual Guidance, and Representing 58% Increase Year-over-Year
  • Generated Operating Cash Flow of $5.5 Million in the Third Quarter and $21.8 Million in the First Nine Months of 2022, Supporting the Increase of Cash Position to $31.3 Million as of September 30, 2022
  • Kamada’s Positive Outlook for the Fourth Quarter Supports Reiteration of Fiscal Year 2022 Revenue Guidance of $125 Million - $135 Million, Representing a 20% to 30% Increase Over 2021 and Adjusted EBITDA Margins Between 12%-15%, More Than 2.5x Over 2021

REHOVOT, Israel and HOBOKEN, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced financial results for the three and nine months ended September 30, 2022.

“Our strong third quarter performance is consistent with our forecasted positive outlook for the second half of the year," said Amir London, Kamada’s Chief Executive Officer. “Our business is beginning to reap the significant benefits of the acquired portfolio of four FDA-approved IgGs, consisting of CYTOGAM®, HEPAGAM B®, VARIZIG® and WINRHO®SDF. We have now completed our rapid transition from our past dependency on GLASSIA® sales to Takeda to a diversified, fully integrated commercial company and a global leader in the plasma-derived specialty market. In the third quarter, we generated total revenues of $32.2 million, representing a 40% increase year-over-year, and overall gross margins increased to 40% as compared to 25% in the third quarter of 2021. Importantly, each of our expected key revenue and profitability drivers, including our new IgG portfolio, as well as KEDRAB® sales and GLASSIA royalty income, contributed significantly to our sales and profitability growth. Based on our expectation for continued revenue growth and enhanced profitability in the fourth quarter of the year, we are reiterating our full-year 2022 financial guidance, which represents a 20% to 30% increase over 2021 revenue and more than 2.5x over 2021 adjusted EBITDA."

“I am pleased to report that over recent months, as part of the establishment of our direct presence in the U.S. market, we deployed a team of U.S.-based experienced sales and medical affair s professionals who have rapidly established our operations in this key market. The U.S. sales team is making good progress in promoting our portfolio of specialty plasma-derived IgG products to physicians and other healthcare practitioners through direct engagement and opportunities at medical conventions. The Medical Affairs team is working to educate physicians, while addressing their scientific and clinical inquiries, including participating in major medical conferences in the U.S. These activities represent the first time in over a decade that these hyper-immune specialty products have been supported by field-based activity in the U.S. We are encouraged by the positive feedback received from key U.S. physicians who are seeking to publish new clinical data related to our portfolio, while conducting educational symposiums that we believe will have a positive impact on the understanding of these products, thereby contributing to continued growth in demand,” continued Mr. London.

“In addition, we continue to make significant progress promoting our commercial portfolio outside the U.S. market. To this end, we recently reported an $11.4 million agreement to supply VARIZIG to an international organization, as well as the extension of an existing tender for the supply, in Canada, of the four IgG products for a total of $22.0 million over the next three years. These significant accomplishments are key factors in ensuring our continued growth. Looking further ahead, we continue to forecast revenue growth at a double-digit rate in the foreseeable years beyond 2022, driven by our proprietary product catalysts, our plasma collection operations, GLASSIA's royalties and the planned launch of eleven biosimilar products in Israel,” concluded Mr. London.

Financial Highlights for the Three Months Ended September 30, 2022

  • Total revenues were $32.2 million in the third quarter of 2022, a 40% increase from the $23.0 million recorded in the third quarter of 2021. Total revenues during the third quarter of 2022 included strong sales from the portfolio of four acquired FDA-approved IgG products. Total revenues included $3.5 million of sales-based royalty income from Takeda based on GLASSIA sales in the U.S.
  • Gross profit and gross margins were $12.9 million and 40%, respectively, in the third quarter of 2022, compared to $5.7 million and 25%, respectively, reported in the third quarter of 2021. The increase in profitability was driven by a positive product sales mix, including sales of our four new IgG products, KEDRAB and GLASSIA royalties. Cost of goods sold in the Company’s Proprietary segment in the third quarter of 2022 included $1.3 million of depreciation expenses associated with intangible assets generated through the IgG products acquisition. Gross profit and gross margins, excluding such intangible assets depreciation, would have been $14.2 million and 44%, respectively.
  • Operating expenses, including R&D, Sales & Marketing (S&M), G&A and other expenses, totaled $10.3 million in the third quarter of 2022, as compared to $6.5 million in the third quarter of 2021. This increase was attributable to increased S&M costs associated with expanded U.S. commercial operations and increased costs associated with accelerating recruitment for the ongoing pivotal Phase 3 clinical trial of Inhaled AAT. S&M costs for the quarter included $0.4 million of depreciation expenses of intangible assets generated through the IgG products acquisition.
  • Finance expense, net for the third quarter of 2022 included a $2.0 million expense associated with the revaluation of the contingent consideration and other long-term liabilities assumed as part of the IgG products acquisition. For more information with respect to such contingent consideration and other long-term liabilities, please refer to Note 5 of the Company’s 2021 financial statements included in the 2021 Annual Report on Form 20-F filed on March 15, 2022, with the Securities and Exchange Commission.
  • Net income was $0.5 million, or $0.01 per share, in the third quarter of 2022, as compared to a net loss of $0.8 million, or $(0.02) per share, in the third quarter of 2021. Excluding depreciation expenses of intangible assets mentioned above and finance expense associated with the revaluation of the contingent consideration and other assumed long-term liabilities, the Company would have recorded net income of $4.3 million, or $0.10 per share, in the third quarter of 2022.
  • Adjusted EBITDA, as detailed in the tables below, was $6.0 million in the third quarter of 2022, as compared to $0.6 million in the third quarter of 2021.
  • Cash provided by operating activities was $5.5 million in the third quarter of 2022, as compared to cash used in operating activities of $2.7 million in the third quarter of 2021.

Financial Highlights for the Nine Months Ended September 30, 2022

  • Total revenues for the first nine months of 2022 were $83.9 million, a 16% increase from the $72.2 million generated in the first nine months of 2021. The increase in revenues is mainly attributable to sales of the acquired four IgG products.
  • Gross profit and gross margins for the first nine months of 2022 were $31.4 million and 37%, respectively, compared to $23.7 million and 33%, respectively, in the prior year period. Gross profit and gross margins in the first nine months of 2022, excluding intangible assets depreciation and a $4.3 million loss related to the labor strike concluded in July 2022, would have been $39.7 million and 47%, respectively, representing a significant increase year-over-year.
  • Operating expenses, including R&D, S&M, G&A and other expenses, totaled $30.9 million in the first nine months of 2022, as compared to $21.1 million in the first nine months 2021. This increase was attributable to an increase in S&M costs associated with the recently acquired portfolio marketing and commercial operation, as well as increased R&D costs, primarily due to advancing the pivotal Phase 3 InnovAATe trial for Inhaled AAT through the opening of new clinical sites and the manufacturing of clinical supply for the study. S&M costs for the first nine months included $1.3 million of depreciation expenses of intangible assets generated through the IgG products acquisition.
  • Finance expense, net for the first nine months of 2022 included a $5.9 million expense associated with the revaluation of the contingent consideration and other long-term liabilities, assumed as part of the IgG products acquisition.
  • Net loss for the first nine months of 2022 was $5.3 million, or $(0.12) per share, as compared to net income of $2.8 million, or $0.06 per share, in the prior year period. Excluding loss associated with the labor strike, depreciation expenses of intangible assets generated through the recent acquisition and finance expense associated with the revaluation of the contingent consideration and other assumed long-term liabilities, the Company would have recorded net income of $10.2 million, or $0.23 per share, in the first nine months of 2022.
  • Adjusted EBITDA, as detailed in the tables below, was $10.6 million in the first nine months of 2022, as compared to $6.7 million in the first nine months of 2021, representing a 58% increase year-over-year, and 13% margins, which is in line with Kamada’s annual guidance. Excluding loss associated with the labor strike, Adjusted EBITDA would have been $14.9 million, representing an 18% margin.
  • Cash provided by operating activities during the first nine months of 2022 was $21.8 million, as compared to cash used in operating activities of $3.9 million during the first nine months of 2021.

Balance Sheet Highlights
As of September 30, 2022, the Company had cash and cash equivalents of $31.3 million, as compared to $18.6 million as of December 31, 2021. Kamada’s strong cash position is driven by continued positive operational cash flows, which is indicative of the significant momentum in the Company’s commercial operations.

Fiscal Year 2022 Guidance
Kamada continues to expect to generate fiscal year 2022 total revenues in the range of $125 million to $135 million, which would represent 20% to 30% growth compared to fiscal year 2021. The Company also anticipates generating adjusted EBITDA during 2022 at a rate of 12% to 15% of total revenues, representing more than 2.5x of the adjusted EBITDA for the year ended December 31, 2021.

Recent Corporate Highlights

  • Awarded extension to existing Canadian supply tender for the portfolio of four specialty IgG products acquired in 2021. The supply extension secures ongoing sales of approximately $7.5 million per year for 2023-2025, with an option to extend for up to an additional two years.
  • Reported acceleration of enrollment in ongoing pivotal Phase 3 clinical trial of Inhaled AAT. The independent DSMB recommended study continuation without modification for the fourth time since study initiation. Based on encouraging safety observed to date, trial inclusion criteria revised to also include patients with severe airflow limitation, thereby expanding the potential patient treatment population. Kamada intends to meet with the FDA and EMA during the first half of 2023 to discuss study progress and potential opportunities to shorten the regulatory pathway.

Conference Call
Kamada management will host an investment community conference call on Tuesday, November 22, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 1-877-407-0792 (from within the U.S.), 1 809-406-247 (from Israel), or 1 201-689-8263 (International) and entering the conference identification number: 13734312. The call will also be webcast live on the Internet at:
https://viavid.webcasts.com/starthere.jsp?ei=1582277&tp_key=8121e668e3.

Non-IFRS financial measures
We present EBITDA and adjusted EBITDA because we use this non-IFRS financial measure to assess our operational performance, for financial and operational decision-making, and as a means to evaluate period-to-period comparisons on a consistent basis. Management believes this non-IFRS financial measure are useful to investors because: (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and provide investors with a meaningful perspective on the current underlying performance of the Company’s core ongoing operations; and (2) they exclude the impact of certain items that are not directly attributable to our core operating performance and that may obscure trends in the core operating performance of the business. Non-IFRS financial measures have limitations as an analytical tool and should not be considered in isolation from, or as a substitute for, our IFRS results. We expect to continue reporting non-IFRS financial measures, adjusting for the items described below, and we expect to continue to incur expenses similar to certain of the non-cash, non-IFRS adjustments described below. Accordingly, unless otherwise stated, the exclusion of these and other similar items in the presentation of non-IFRS financial measures should not be construed as an inference that these items are unusual, infrequent or non-recurring. EBITDA and adjusted EBITDA are not recognized terms under IFRS and do not purport to be an alternative to IFRS terms as an indicator of operating performance or any other IFRS measure. Moreover, because not all companies use identical measures and calculations, the presentation of EBITDA and adjusted EBITDA may not be comparable to other similarly titled measures of other companies. EBITDA and adjusted EBITDA are defined as net income (loss), plus income tax expense, plus or minus financial income or expenses, net, plus or minus income or expense in respect of securities measured at fair value, net, plus or minus income or expenses in respect of currency exchange differences and derivatives instruments, net, plus depreciation and amortization expense, plus non-cash share-based compensation expenses and certain other costs.

About Kamada
Kamada Ltd. (the “Company”) is a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities. The Company’s strategy is focused on driving profitable growth from our current commercial activities as well as our manufacturing and development expertise in the plasma-derived biopharmaceutical market. The Company’s commercial products portfolio includes its developed and FDA approved products GLASSIA® and KEDRAB® as well as its recently acquired FDA approved plasma-derived hyperimmune products CYTOGAM®, HEPAGAM B®, VARIZIG® and WINRHO®SDF. The Company has additional four plasma-derived products which are registered in markets outside the U.S. The Company distributes its commercial products portfolio directly, and through strategic partners or third-party distributors in more than 30 countries, including the U.S., Canada, Israel, Russia, Brazil, Argentina, India and other countries in Latin America and Asia. The Company has a diverse portfolio of development pipeline products including an inhaled AAT for the treatment of AAT deficiency for which the Company is currently conducting the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. The Company leverages its expertise and presence in the Israeli pharmaceutical market to distribute in Israel more than 20 products that are manufactured by third parties and have recently added eleven biosimilar products to its Israeli distribution portfolio, which, subject to EMA and the Israeli MOH approvals, are expected to be launched in Israel through 2028. FIMI Opportunity Fund, the leading private equity investor in Israel, is the Company’s lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares.

Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, including statements regarding: 1) fiscal year 2022 guidance, 2) revenue growth at a double-digit rate in the foreseeable years beyond 2022, driven by Kamada’s proprietary product catalysts, plasma collection operations, GLASSIA's royalties and the planned launch of 11 biosimilar products in Israel, 3) continued revenue growth and enhanced profitability in the fourth quarter of the year, 4) Kamada becoming a diversified, fully integrated commercial company and a global leader in the plasma-derived specialty market, 5) optimism about the positive feedback received from key U.S. physicians to enable the expansion of sales of our IgG portfolio, 6) the encouraging safety observed to date relating to the Phase 3 clinical trial of Inhaled AAT, and 7) planned meeting with the FDA and EMA during the first half of 2023 to discuss study progress and potential opportunities to shorten the regulatory pathway. Forward-looking statements are based on Kamada’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, the continued evolvement of the COVID-19 pandemic, its scope, effect and duration, availability of sufficient raw materials required to maintain manufacturing plans, disruption to the supply chain due to COVID-19 pandemic, continuation of inbound and outbound international delivery routes, continued demand for Kamada’s products, financial conditions of the Company’s customer, suppliers and services providers, Kamada’s ability to integrate the new product portfolio into its current product portfolio, Kamada’s ability to grow the revenues of its new product portfolio, and leverage and expand its international distribution network, ability to reap the benefits of the recent acquisition of the plasma collection center, including the ability to open additional U.S. plasma centers, and acquisition of the FDA-approved plasma-derived hyperimmune commercial products, the ability to continue enrollment of the pivotal Phase 3 InnovAATe clinical trial in new locations, unexpected results of clinical studies, Kamada’s ability to manage operating expenses, additional competition in the markets that Kamada competes, regulatory delays, prevailing market conditions and the impact of general economic, industry or political conditions in the U.S., Israel or otherwise, and other risks detailed in Kamada’s filings with the U.S. Securities and Exchange Commission (the “SEC”) including those discussed in its most recent Annual Report on Form 20-F and in any subsequent reports on Form 6-K, each of which is on file or furnished with the SEC and available at the SEC’s website at www.sec.gov. The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com

Bob Yedid
LifeSci Advisors, LLC
646-597-6989
Bob@LifeSciAdvisors.com


CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

  As of September 30,  As of
December 31,
 
  2022  2021  2021 
  Unaudited  Audited 
  U.S Dollars in thousands 
Assets         
Current Assets         
Cash and cash equivalents $31,252  $99,840  $18,587 
Trade receivables, net  23,997   26,548   35,162 
Other accounts  receivables  6,884   4,392   8,872 
Inventories  73,029   48,163   67,423 
Total Current Assets  135,162   178,943   130,044 
             
Non-Current Assets            
Property, plant and equipment, net  25,898   25,856   26,307 
Right-of-use assets  2,793   3,361   3,092 
Intangible assets, Goodwill and other long-term assets  148,620   3,380   153,663 
Contract assets  7,164   4,987   5,561 
Total Non-Current Assets  184,475   37,584   188,623 
Total Assets $319,637  $216,527  $318,667 
Liabilities            
Current Liabilities            
Current maturities of bank loans $4,444  $52  $2,631 
Current maturities of lease liabilities  1,004   1,181   1,154 
Current maturities of other long term liabilities  25,095   -   17,986 
Trade payables  30,619   19,010   25,104 
Other accounts payables  7,948   6,346   7,142 
Deferred revenues  40   -   40 
Total Current Liabilities  69,150   26,589   54,057 
             
Non-Current Liabilities            
Bank loans  14,074   -   17,407 
Lease liabilities  2,414   3,283   3,160 
Contingent consideration  20,705   -   21,995 
Other long-term liabilities  39,915   -   43,929 
Deferred revenues  15   3,575   15 
Employee benefit liabilities, net  813   1,467   1,280 
Total Non-Current Liabilities  77,936   8,325   87,786 
             
Shareholder’s Equity            
Ordinary shares  11,732   11,720   11,725 
Additional paid in capital net  210,355   210,005   210,204 
Capital reserve due to translation to presentation currency  (3,490)  (3,490)  (3,490)
Capital reserve from hedges  (257)  35   54 
Capital reserve from share-based payments  5,427   4,817   4,643 
Capital reserve from employee benefits  212   (320)  (149)
Accumulated deficit  (51,428)  (41,154)  (46,163)
Total Shareholder’s Equity  172,551   181,613   176,824 
Total Liabilities and Shareholder’s Equity $319,637  $216,527  $318,667 



CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

  Nine months period ended  Three months period ended  Year ended 
  September 30,  September 30,  December 31, 
  2022  2021  2022  2021  2021 
  Unaudited  Unaudited  Audited 
  U.S Dollars In thousands 
                
Revenues from proprietary products $67,198  $57,316  $25,580  $17,123  $75,521 
Revenues from distribution  16,702   14,857   6,637   5,911   28,121 
                     
Total revenues  83,900   72,173   32,217   23,034   103,642 
                     
Cost of revenues from proprietary products  37,856   35,605   13,151   12,078   48,194 
Cost of revenues from distribution  14,632   12,835   6,196   5,226   25,120 
                     
Total cost of revenues  52,488   48,440   19,347   17,304   73,314 
                     
Gross profit  31,412   23,733   12,870   5,730   30,328 
                     
Research and development expenses  10,181   7,909   3,118   2,545   11,357 
Selling and marketing expenses  10,435   3,803   3,843   1,256   6,278 
General and administrative expenses  9,481   8,803   3,165   2,691   12,636 
Other expenses  801   612   182   42   753 
Operating income (loss)  514   2,606   2,562   (804)  (696)
                     
Financial income  32   277   29   68   295 
Income (expenses) in respect of currency exchange differences and derivatives instruments, net  756   74   163   (48)  (207)
Financial Income (expense) in respect of contingent consideration and other long- term liabilities.  (5,924)  -   (2,049)  -   (947)
Financial expenses  (583)  (178)  (211)  (61)  (330)
Income before tax on income  (5,205)  2,779   494   (845)  (1,885)
Taxes on income  60   -   10   -   345 
                     
Net Income (loss) $(5,265) $2,779  $484  $(845) $(2,230)
                     
Other Comprehensive Income (loss):                    
Amounts that will be or that have been reclassified to profit or loss when specific conditions are met                    
Gain (loss) on cash flow hedges  (830)  25   (46)  68   185 
Net amounts transferred to the statement of profit or loss for cash flow hedges  519   (347)  231   (91)  (488)
Items that will not be reclassified to profit or loss in subsequent periods:                    
Remeasurement gain (loss) from defined benefit plan  361   -   (59)  -   171 
Total comprehensive income (loss) $(5,215) $2,457  $610  $(868) $(2,362)
                     
Earnings per share attributable to equity holders of the Company:                    
Basic net earnings per share $(0.12) $0.06  $0.01  $(0.02) $(0.05)
Diluted net earnings per share $(0.12) $0.06  $0.01  $(0.02) $(0.05)



CONSOLIDATED STATEMENTS OF CASH FLOWS

  Nine months period Ended  Three months period
Ended
  Year Ended 
  September, 30  September, 30  December 31, 
  2022  2021  2022  2021  2021 
  Unaudited  Audited 
  U.S Dollars In thousands 
Cash Flows from Operating Activities               
Net income (loss) $(5,265) $2,779  $484  $(845) $(2,230)
                     
Adjustments to reconcile net income to net cash provided by (used in) operating activities:                    
                     
Adjustments to the profit or loss items:                    
                     
Depreciation and impairment  9,143   3,612   3,055   1,240   5,609 
Financial expenses (income), net  5,719   (173)  2,068   41   1,189 
Cost of share-based payment  935   504   366   134   529 
Taxes on income  60   -   10   -   345 
Change in employee benefit liabilities, net  (106)  61   (10)  38   45 
   15,751   4,004   5,489   1,453   7,717 
Changes in asset and liability items:                    
                     
Decrease (increase) in trade receivables, net  10,744   (4,446)  (6,358)  1,200   (12,861)
Decrease (increase) in other accounts receivables  2,917   1,556   844   (73)  (1,634)
Decrease (increase) in inventories  (5,606)  (5,963)  (8,509)  (3,562)  (2,373)
Decrease (increase) in deferred expenses  (2,596)  (4,759)  (2,112)  (2,397)  (6,883)
Increase (decrease) in trade payables  5,895   2,725   13,738   1,586   7,917 
Increase (decrease) in other accounts payables  566   (1,482)  2,083   (683)  (392)
Decrease in deferred revenues  -   1,550   -   550   1,815 
   11,920   (10,819)  (314)  (3,379)  (14,411)
Cash received (paid) during the period for:                    
                     
Interest paid  (550)  (139)  (170)  (32)  (228)
Interest received  15   357   12   140   375 
Taxes paid  (27)  (32)  (9)  (9)  (42)
   (562)  186   (167)  99   105 
                     
Net cash provided by (used in) operating activities $21,844  $(3,850) $5,492  $(2,672) $(8,819)



CONSOLIDATED STATEMENTS OF CASH FLOWS

  Nine months period Ended  Three months period Ended  Year Ended 
  September, 30  September, 30  December 31, 
  2022  2021  2022  2021  2021 
  Unaudited  Audited 
  U.S Dollars In thousands 
Cash Flows from Investing Activities               
                
Investment in short term investments, net $-  $39,083  $-  $36,116  $39,083 
Purchase of property and equipment and intangible assets  (2,807)  (2,986)  (1,616)  (1,523)  (3,730)
Business combination  -   (1,404)  -   -   (96,403)
Net cash provided by (used in) investing activities  (2,807)  34,693   (1,616)  34,593   (61,050)
                     
Cash Flows from Financing Activities                    
                     
Proceeds from exercise of share base payments  7   14   1   4   19 
Receipt of long-term loans  -   -       -   20,000 
Repayment of lease liabilities  (842)  (903)  (269)  (308)  (1,221)
Repayment of long-term loans  (1,517)  (221)  (1,116)  (15)  (205)
Repayment of other long-term liabilities  (4,120)  -   (877)  -   - 
Net cash provided by (used in) financing activities  (6,472)  (1,110)  (2,261)  (319)  18,593 
                     
Exchange differences on balances of cash and cash equivalent  100   (90)  (296)  (178)  (334)
                     
Increase (decrease) in cash and cash equivalents  12,665   29,643   1,319   31,424   (51,610)
                     
Cash and cash equivalents at the beginning of the period  18,587   70,197   29,933   68,416   70,197 
                     
Cash and cash equivalents at the end of the period $31,252  $99,840  $31,252  $99,840  $18,587 
                     
Significant non-cash transactions                    
Right-of-use asset recognized with corresponding lease liability $526  $769  $230  $181  $845 
Purchase of property and equipment and Intangible assets $134  $352  $134  $352  $1,001 



NON-IFRS MEASURES – ADJUSTED EBITDA

  Nine months period ended  Three months period ended  Year ended 
  September 30,  September 30,  December 31, 
  2022  2021  2022  2021  2021 
  In thousands 
Net income $(5,265) $2,779  $484  $(845 $(2,230)
Taxes on income  60   -   10   -   345 
Financial expense (income), net  5,719   (173)  2,068   41   1,189 
Depreciation and amortization expense  9,143   3,612   3,055   1,240   5,609 
Non-cash share-based compensation expenses  935   504   366   134   529 
Adjusted EBITDA $10,592  $6,722  $5,983  $570  $5,442